biotech best performing sectors

October 2002 Stock Report

The October 2002 Stock Report, published by Recombinant Capital and Signals, is the 29th in a series. It includes detailed financial data on 235 publicly traded biotechnology stocks, based on their closing prices on October 31, 2002.

(To access the September 2002 Stock Report, click here. For the others -- February 2000 through August 2002 -- click here to go to Signals' Table Of Contents. [We did not publish stock reports for the June 2001 - September 2001 time frame.] All the Stock Reports are listed under the Signals vs. Noise section. The spreadsheets underlying these articles are quite large, so please be patient while you download them.)

We've classified the companies on the list into 18 separate categories, based largely on either technology or disease focus. These categories can be found in the table that follows, which provides a summary of the underlying data and the average values (the sum of all values divided by the number of values) for each. Because the average value tends to be distorted when there are extreme values in a set (as occurs in the biotech stocks as a group and even within groups), we've also calculated the median (mid-point) for each set of data and for the entire group. We believe that the median values reflect a more realistic financial profile for the biotech stocks.

If you wish to access the entire spreadsheet (HTML 221k), just click here (and remember, it's a large spreadsheet and takes time to download. Don't despair if your screen seems to remain forever blank after the download; it might take a minute or so for the spreadsheet to appear.) If you wish to access the section of the spreadsheet that concerns a specific category (i.e., cancer or gene therapy), click on that category in the summary table below.

Company % 52 wk high on 10/31/02 % change from 10/26/01 Market cap ($M) Cash & Mkt. Sec. ($M) Tech value ($M) Tech value/staff ($M) Est. burn rate ($M) Survival index (yrs) Equity multiple
1st
Generation
Genomics
Average:
Median:
22%







Genomic Supply
Average:
Median:
35%
GenomicTargets
Average:
Median:
25%

Agbio/Enviro.
Average:
Median:
54%
Autoimmune
Average:
Median:
43%
Cancer
Average:
Median:
30%
Cardiovascular
Average:
Median:
49%

Chemistry
Average:
Median:
41%
Average:
Median:
37%
Delivery
Average:
Median:
34%
Diagnostic/Imaging
Average:
Median:
47%
Gene Therapy
Average:
Median:
29%
Infection
Average:
Median:
43%

Metabolic
Average:
Median:
43%

Other
Average:
Median:
47%

Revenue-Driven
Average:
Median:
66%
Screening
Average:
Median:
37%
Wound
Average:
Median:
42%
Grand
Average:
Median:
39%


Cash flow are best!!